VETERINARY ToDAY
ISSN: 2583-8288
Technical Article
Published on: 28.02.2025

Role of vaccines in reducing antimicrobial resistance

Dr. Amit Gangwar, Dr. Himangi Gupta and Dr. Arivazhagan Anbazhagan
MVSc. Scholar,Division of Veterinary Public Health and Epidemiology
(ICAR- Indian Veterinary Research Institute)
DOI:/10.5281/Vettoday.14995713

Introduction

The introduction of antibiotics in the mid-20th century revolutionized clinical practice by equipping healthcare professionals with a potent tool to combat and prevent infectious diseases. This development has resulted in the preservation of millions of lives globally.

The incidence of illness and death due to bacterial infections, as well as associated healthcare expenses, have been markedly reduced owing to the availability of efficacious antibiotics. Despite the remarkable therapeutic advantages provided by these medications, the enthusiasm among clinicians has gradually reduced in recent years due to a growing concern regarding their effectiveness. This concern is primarily attributed to antimicrobial resistance (AMR), a phenomenon wherein pathogens evolve to withstand the drugs designed to eliminate them. AMR is one of the most pressing global health threats, arising due to the excessive and inappropriate use of antibiotics, antivirals, antifungals, and antiparasitic agents. The emergence of drug-resistant pathogens has led to increased mortality, prolonged illnesses, and a significant burden on healthcare systems. Based on current trends in the escalation of AMR, projections indicate that by the year 2050, AMR could result in the annual loss of 10 million lives. This number would surpass the current annual mortality rate from cancer, which stands at 8.2 million. it is estimated that globally, at least 700,000 individuals succumb to infections caused by antibiotic-resistant pathogens each year. This mortality rate surpasses the combined deaths attributable to tetanus, cholera, and measles. It is estimated that, in 2019, 7.7 million deaths were associated with 33 different bacterial infections, with almost 5 million of these deaths being associated with AMR. According to estimates by organizations like KPMG and RAND Europe, if antimicrobial resistance continues to rise, it could lead to a reduction in global GDP by 2-3.5% by the year 2050.

The development of novel antimicrobials is crucial, non-pharmaceutical interventions such as vaccines play a pivotal role in preventing infections and reducing the dependency on antibiotics. Vaccines help control the spread of resistant strains, thereby limiting the evolution and transmission of AMR. Understanding the mechanisms through which vaccines contribute to combating AMR is essential for advancing global public health strategies.

Challenges in Developing New Antibiotics

The development of new antimicrobials faces several scientific and commercial obstacles. Firstly, companies and researchers must identify lead molecules that effectively target and kill bacteria through specific mechanisms. Secondly, optimizing the safety and tolerability of these compounds is a significant challenge. Additionally, the development process is hindered by a lack of funding for costly clinical trials and limited market interest in newly approved antibiotic drugs.

Vaccines as powerful tools to fight AMR

There are numerous well-documented strategies to mitigate the global burden of antimicrobial resistance. These include improved sanitation and hygiene practices, financial support for the development of novel antibiotic classes, antibiotic stewardship programs, educational initiatives to discourage inappropriate antibiotic use (such as for viral infections), and the cessation of routine antibiotic use in livestock production. These interventions have demonstrated significant benefits upon implementation. However, it is less widely recognized that prophylactic vaccines are also highly effective and valuable in the fight against AMR. Vaccines function by training the immune system to identify and respond to pathogens, thereby mounting a rapid and effective immune defence. This process either prevents the establishment of an infection or disease or reduces the severity of the disease.

Vaccination serves as an effective strategy to combat antimicrobial resistance by directly limiting the spread of resistant pathogens through the production of specific antibodies, thereby reducing or eliminating the need for antibiotics. This has been well-documented with vaccines for *Haemophilus influenzae* type b, Pneumococci, Meningococci, and Rotavirus. In a 2018 clinical trial involving children aged 6 to 35 months, those who received quadrivalent Influenza vaccines had a 47% lower incidence of influenza compared to the placebo group, and antibiotic prescriptions were reduced by 50%.

How vaccines can help prevent AMR

1- **By preventing disease and the proliferation of bacteria-** Vaccines generally prevent pathogens from establishing an infection in the host by inducing immunity prior to exposure. By emphasizing prevention over treatment, vaccines hinder the development of diseases immediately following pathogen exposure, thus reducing the likelihood of bacterial mutations and resistance. Consequently, this also decreases the spread of resistant genes to other bacteria.

2- **By mechanisms of action less prone to inducing resistance-** Vaccines typically elicit immune responses targeting multiple epitopes on each antigen, necessitating numerous bacterial mutations to evade vaccine-induced immunity. While antibiotic resistance is a natural and relatively swift phenomenon in some pathogens, this resistance is not exacerbated by vaccines. Most vaccines maintain their protective efficacy over extended periods.

3- **By reducing antibiotic use due to fewer infections-** By preventing bacterial infections from occurring or spreading in the population, vaccination reduces the use of antibiotics that would have been used to treat infections and thereby indirectly reduces the risk of AMR developing. For example, vaccines against ***Streptococcus pneumoniae*, *Haemophilus influenzae* type b (Hib), and *Bordetella pertussis*** have significantly lowered infections caused by these bacteria, leading to a decrease in antibiotic prescriptions.

4- **By preventing resistant strains from occurring and spreading-** By inducing immunity, vaccines prevent the initial establishment and proliferation of infections, which reduces the necessity for antibiotic use. This helps in avoiding the selective pressure that typically leads to the emergence of resistant strains. Vaccines limit the spread of infectious diseases within communities, thus reducing the transmission of resistant strains from one individual to another.

5- **By preventing antibiotic misuse-** A comprehensive review of 96 studies found that influenza vaccines decrease antibiotic use in healthy adults and children aged 6 months to 14 years. This reduction in prescriptions through vaccination could significantly impact antibiotic resistance (Buckley et al., 2019).

6- **By preventing viral diseases prone to bacterial co-infections or superinfections requiring antibiotics-** Vaccines have the potential to reduce the need for antibiotics (and antivirals) to treat co-infections or superinfections by preventing the primary infection from occurring in the first place. Vaccines also prevent secondary bacterial infections following viral illnesses such as influenza, which often necessitate antibiotic treatment.

Effect of Vaccines on AMR Mechanisms

The role of vaccines extends beyond reducing infection rates, they also influence microbial ecology and evolutionary pathways of resistance. By preventing infections from **AMR-associated pathogens** such as *Neisseria gonorrhoeae* and *Mycobacterium tuberculosis*, vaccines help maintain the efficacy of existing antibiotics. Moreover, vaccines lower pathogen colonization rates and bacterial load in vaccinated individuals, thereby reducing horizontal gene transfer of resistance genes among bacterial populations. This is particularly important in healthcare settings where resistant strains are prevalent. Furthermore, vaccines targeting **toxin-producing bacteria** like *Clostridioides difficile* can help reduce the need for broad-spectrum antibiotics, further curbing AMR. Through these mechanisms, vaccines contribute to breaking the cycle of resistance development and dissemination.

Current Vaccines in Preclinical and Clinical Development and Challenges

Several vaccines targeting AMR-associated pathogens are in various stages of development. Notable candidates include vaccines against *Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus,* and *Escherichia coli*, which are responsible for a significant proportion of drug-resistant infections worldwide. Additionally, advancements in mRNA technology and reverse vaccinology have accelerated vaccine development, offering new avenues for targeting AMR pathogens. However, significant challenges remain, including **high costs, limited efficacy in immunocompromised individuals, and serotype diversity** in bacteria, which may lead to partial protection. Additionally, the emergence of immune escape variants necessitates constant surveillance and vaccine modifications. Addressing these barriers requires collaborative efforts from governments, pharmaceutical industries, and global health organizations to ensure equitable vaccine distribution and accessibility.

Future Perspectives

The future of vaccine-based AMR mitigation relies on the development of next-generation vaccines, including those utilizing **nanotechnology, adjuvant optimization, and artificial intelligence-driven antigen selection**. Advances in **universal vaccines** capable of targeting conserved bacterial components may provide broad-spectrum protection against resistant strains. Additionally, the integration of **vaccines into routine immunization programs**, especially in low- and middle-income countries (LMICs), can significantly reduce the AMR burden in regions with high antibiotic misuse. Policymakers and researchers must work together to strengthen **surveillance systems, promote vaccine uptake, and encourage public awareness campaigns**. The synergistic approach of combining vaccination with antimicrobial stewardship programs will be crucial in mitigating the AMR crisis and safeguarding global health.

Conclusion

vaccines serve as a powerful tool in the fight against AMR by reducing infection rates, limiting antibiotic use, and curbing resistance gene transmission. Continued investment in vaccine research, coupled with strategic implementation, will play a pivotal role in controlling the AMR pandemic and ensuring the longevity of current and future antimicrobial agents.

Reference:

Buchya, P., Ascioglua, S., Buissonb, Y., Dattaa, S., Nissena, M., Tambyahc, P.A. & Vongd, S., "Impact of vaccines on antimicrobial resistance." International Journal of Infectious Diseases **90** (2020): 188–196

Buckley B.S., Henschke N., Bergman H., Skidmore B., Klemm E.J. & Villanueva G., Impact of vaccination on antibiotic usage: a systematic review and metaanalysis. Clinical Microbiology and Infection. **25**(2019):1213–25.

Costanzo, V. and Roviello, G.N. "The Potential Role of Vaccines in Preventing Antimicrobial Resistance (AMR): An Update and Future Perspectives". Vaccines **11** (2023): 333.

Jansen, K.U. and Anderson, A. S. "The role of vaccines in fighting antimicrobial resistance (AMR)". Human Vaccines & Immunotherapeutics. **14** (2018) 9: 2142–2149

WHO- World health organization. "Estimating the impact of vaccines in reducing antimicrobial resistance and antibiotic use" (2024).